Search results
Showing 351 to 400 of 8100 results
Early value assessment (EVA) guidance on artificial intelligence technologies to aid contouring for radiotherapy treatment planning in people having external be...
View recommendations for HTE11Show all sections
NICE has today (26 September 2023) published draft guidance for public consultation that does not recommend trastuzumab deruxtecan for treating advanced HER2-low breast cancer in adults.
KardiaMobile 6L for measuring cardiac QT interval in adults having antipsychotic medication (HTE10)
Early value assessment (EVA) guidance on KardiaMobile 6L for measuring cardiac QT interval in adults having antipsychotic medication....
Evidence-based recommendations on removal, preservation and reimplantation of ovarian tissue for restoring fertility after gonadotoxic treatment. This involves surgically removing ovarian tissue before a treatment for cancer or other medical condition that can damage the ovaries (gonadotoxic treatment) begins. The ovarian tissue is then frozen to be reimplanted after the gonadotoxic treatment is finished, to restore fertility.
View recommendations for IPG772Show all sections
Working examples of quality improvement in health and social care services. Quality improvement, efficiency changes, cost savings, good practice, shared learning.
Birch bark extract for treating epidermolysis bullosa (HST28)
Evidence-based recommendations on birch bark extract (Filsuvez) for treating partial thickness wounds associated with dystrophic and junctional epidermolysis bullosa in people aged 6 months and over.
Evidence-based recommendations on pembrolizumab (Keytruda) for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency in adults.
This quality standard covers assessing, diagnosing and managing chronic obstructive pulmonary disease (COPD). It describes high-quality care in priority areas for improvement.
View quality statements for QS10Show all sections
Sections for QS10
- Quality statements
- Quality statement 1: Diagnosis with spirometry
- Quality statement 2: Inhaler technique
- Quality statement 3: Assessment for long-term oxygen therapy
- Quality statement 4: Pulmonary rehabilitation for stable COPD and exercise limitation
- Quality statement 5: Pulmonary rehabilitation after an acute exacerbation
- Quality statement 6: Emergency oxygen during an exacerbation
- Quality statement 7: Non-invasive ventilation
In the UK, medicines need to have a licence before they can be widely used. Licensing of medicines To get a licence, the manufacturer of the medicine
Patient safety and surgical innovation – why new isn't always better
Jane Blazeby, Professor of Surgery, University of Bristol, University Hospitals Bristol and Weston and the NIHR Bristol Biomedical Research Centre, talks about the research she’s led to explore and address optimism bias and other issues in surgical innovation.
A new draft NICE guideline for inherited ovarian cancer published today (15 September 2023), recommends more people are tested for genes linked to ovarian cancer.
Support for voluntary and community sector (VCS) organisations
Public involvement support for voluntary and community sector organisations
First in new class of treatment for acute migraine recommended by NICE set to benefit thousands
The first in a new class of treatment to be recommended by NICE for treating acute migraine will soon be available on the NHS to around 13,000 people.
NICE Medicines and technologies programme: adoption team
Evidence-based recommendations on transurethral water-jet ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia. This involves injecting a high-speed jet of water into the prostate to destroy some of the prostate tissue and widen the urethra.
View recommendations for IPG770Show all sections
Evidence-based recommendations on cryotherapy for chronic rhinitis. This involves destroying a nerve in the nose to reduce chronic rhinitis symptoms.
View recommendations for IPG771Show all sections
NICE committee recommends tirzepatide as new treatment option for people with type 2 diabetes
Around 180,000 people with difficult to manage type 2 diabetes could benefit from a new treatment option recommended by NICE
This guideline covers assessing and managing suspected or confirmed cirrhosis in people who are 16 years or older. It aims to improve how cirrhosis is identified and diagnosed, and gives advice on the monitoring, prevention and early management of complications.
Recommendation ID CG189/04 Question What is the effectiveness and cost effectiveness of bariatric surgery in achieving weight loss and
Recommendation ID CG189/03 Question What is the effectiveness and cost effectiveness of bariatric surgery in achieving weight loss and
A selection of resources to help you deliver high-quality care and services using NICE guidance
Spinal metastases and metastatic spinal cord compression (NG234)
This guideline covers recognition, referral, investigation and management of spinal metastases and metastatic spinal cord compression (MSCC). It is also relevant for direct malignant infiltration of the spine and associated cord compression. It aims to improve early diagnosis and treatment to prevent neurological injury and improve prognosis.
Mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy (TA913)
Evidence-based recommendations on mavacamten (Camzyos) for symptomatic obstructive hypertrophic cardiomyopathy.
Spinal metastases and metastatic spinal cord compression (QS56)
This quality standard covers diagnosis and management of spinal metastases and metastatic spinal cord compression. It describes high-quality care in priority areas for improvement.
View quality statements for QS56Show all sections
Sections for QS56
- Quality statements
- Quality statement 1: Information about recognising the symptoms of metastatic spinal cord compression
- Quality statement 2: Imaging and treatment plans for adults with suspected spinal metastases
- Quality statement 3: Imaging for adults with suspected metastatic spinal cord compression
- Quality statement 4: Coordinating investigations for adults with suspected metastatic spinal cord compression
- Quality statement 5: Coordinating care for adults with metastatic spinal cord compression
- Quality statement 6: Radiotherapy for metastatic spinal cord compression
- Quality statement 7: Supportive care and rehabilitation
Early value assessment (EVA) guidance on guided self-help digital cognitive behavioural therapy for children and young people with mild to moderate symptoms of ...
Find out more about quality standards advisory committee 2 members at NICE
An advisory service from the UK’s National Institute for Health and Care Excellence to help other countries improve their nation’s health and wellbeing
Get expert advice and support from NICE International, part of the UK’s National Institute for Health and Care Excellence, for a project in your country
Evidence-based recommendations on semaglutide (Wegovy) for managing overweight and obesity in adults.
Consultation launched on draft guidance for the assessment and management of acute respiratory infections in people over 16
This guideline covers identifying and managing otitis media with effusion (OME), also known as ‘glue ear’, in children younger than 12 years. It aims to improve hearing and quality of life in children with OME.
Find individual child abuse and neglect recommendations quickly and links to full guideline
Resources to help with planning ahead for NICE guidance, understanding where you are now, and conducting improvement initiatives.
International health technology assessment collaboration expands
The international collaboration between six health technology assessment bodies from across the UK, Australia and Canada has welcomed two further HTA bodies.
Around 100,000 fewer colonoscopies expected to take place each year following updated NICE guidance
Tens of thousands of people a year could be spared the need for a colonoscopy following new guidance from NICE.
Evidence-based recommendations on quantitative faecal immunochemical testing to guide colorectal cancer pathway referral in primary care
Ectopic pregnancy and miscarriage: diagnosis and initial management (NG126)
This guideline covers diagnosing and managing ectopic pregnancy and miscarriage in women with complications, such as pain and bleeding, in early pregnancy (that is, up to 13 completed weeks of pregnancy). It aims to improve how early pregnancy loss is diagnosed, and the support women are given, to limit the psychological impact of their loss.
Details and meeting dates of the antimicrobials evaluation committee
Information and benefits about shared decision making. Includes links to patient decision aids.
Public health advisory committees (PHACs) are the standing committees responsible for the development of our public health guidance. Come to a meeting
Find out what a NICE lay members does
You should run a mini competition for the following lots only: lot 2: print books lot 3: electronic books lot 4: print and electronic journals.
Our experts can offer advice and support in contextualising our guidelines, or helping you adapt our content to your country or local context.
This indicator covers the percentage of patients on the CKD register and with an albumin to creatinine ratio (ACR) of 70 mg/mmol or more, without diabetes, who are currently treated with an ARB or an ACE inhibitor. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM247
This indicator covers the percentage of patients on the CKD register and currently treated with an ARB or an ACE inhibitor who are also currently treated with an SGLT2 inhibitor if they have either: no type 2 diabetes and a urine ACR of 22.6 mg/mmol or more, or type 2 diabetes and a urine ACR 3 mg/mmol or more. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM246
This indicator covers the percentage of patients with a total cholesterol reading in the preceding 12 months greater than 7.5 mmol/litre who have been: diagnosed with secondary hyperlipidaemia, or clinically assessed for familial hypercholesterolaemia, or referred for assessment for familial hypercholesterolaemia, or genetically diagnosed with familial hypercholesterolaemia. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM245
Kidney conditions: CKD and blood pressure when ACR 70 or more
This indicator covers the percentage of patients on the CKD register and with an albumin to creatinine ratio (ACR) of 70 mg/mmol or more, without moderate or severe frailty, in whom the last blood pressure reading (measured in the preceding 12 months) is less than 125/75 mmHg if using ambulatory or home monitoring, or less than 130/80 mmHg if monitored in clinic. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM248.
This indicator covers the contractor establishing and maintaining a register of patients with coronary heart disease. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM235
This indicator covers the contractor establishing and maintaining a register of all cancer patients excluding non-melanotic skin cancers. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM234
Diabetes: blood pressure (without moderate or severe frailty)
This indicator covers the percentage of patients with diabetes on the register, aged 79 years and under without moderate or severe frailty, in whom the last blood pressure reading (measured in the preceding 12 months) is less than 135/85 mmHg if using ambulatory or home monitoring, or less than 140/90 mmHg if measured in clinic. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM233